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Background: Head and neck cancer (HNC) belongs to a group of heterogeneous
disease with distinct patterns of behavior and presentation. TNFRSF10B, a tumor
suppressor gene mapped on chromosome 8. Mutation in candidate gene is
responsible for the loss of chromosome p arm which is frequently observed in head
and neck tumors. TNFRSF10B inhibits tumor formation through apoptosis but
deregulation encourages metastasis, migration and invasion of tumor cell tissues.
Results: Structural modeling was performed by employing MODELLER (9v10). A
suitable template [2ZB9] was retrieved from protein databank with query coverage
and sequence identity of 84% and 30% respectively. Predicted Model evaluation
form Rampage revealed 93.2% residues in favoured region, 5.7% in allowed region
while only 1 residue is in outlier region. ERRAT and ProSA demonstrated 51.85%
overall quality with a −1.08 Z-score of predicted model. Molecular Evolutionary
Genetics Analysis (MEGA 5) tool was executed to infer an evolutionary history of
TNFRSF10B candidate gene. Orthologs and paralogs [TNFRSF10A & TNFRSF10D]
protein sequences of TNFRSF10B gene were retrieved for developed ancestral
relationship. Topology of tree presenting TNFRSF10A gene considered as outgroup.
Human and gorilla shared more than 90% similarities with conserved amino acid
sequence. Virtual screening approach was appliedfor identification of novel inhibitors.
Library (Mcule) was screened for novel inhibitors and utilized the scrutinized lead
compounds for protein ligand docking. Screened lead compounds were further
investigated for molecular docking studies. STRING server was employed to explore
protein-protein interactions of TNFRSF10B target protein. TNFSF10 protein showed
highest 0.999 confidence score and selected protein-protein docking by utilizing
GRAMM-X server. In-silico docking results revealed I-58, S-90 and A-62 as most active
interacting residues of TNFRSF10B receptor protein with R-130, S-156 and R-130 of
TNFSF10B ligand protein.
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Conclusion: Current research may provide a backbone for understanding structural
and functional insights of TNFRSF10B protein. The designed novel inhibitors and
predicted interactions might serve to inhibit the disease. Effective in-vitro potent
ligands are required which will be helpful in future to design a drug to against Head
and neck cancer disease. There is an urgent need for affective drug designing of head
and neck cancer and computational tools for examining candidate genes more
efficiently and accurately are required.
Keywords: Head and neck cancer, Modeling, Tumor necrosis factor, TNFRSF10B,
Docking, MODELLER, Phylogenetic, Virtual screening, Inhibitors, BioinformaticsBackground
HNC is the sixth most occurring cancers worldwide [1] whereas in Pakistan, the
second most prevalent cancer affecting the pharynx, larynx and oral cavity [2].
Multigenic nature and environmental agents made heterogeneous and complex epi-
demiology of disease [3]. Different genetic polymorphisms are reported in enzymes
involved in the metabolization of alcohol and tobacco greatly increases the risk of
Squamous Cell Carcinoma of Head and Neck cancer (SCCHN) [4,5]. Morbidity and
prognosis differ from patient to patient depending on causative agents, anatomical
site and the stage of disease.
DNA modifications and structural variations in the genomic content of cell controlling
gene expression are responsible for cancers. Deletions and duplications of chromosomal
segments or even whole chromosome lead to the genomic instability causing genetic alter-
ations [6]. DNA modifications are greatly responsible for change in expression level of
HNC [6,7]. Genetic events result in the activation of proto-oncogenes and inactivation of
tumor suppressor genes or both, leading to the development of SCCHN [7,8].
Tumor Necrosis Factor (TNF) is a mediator pro-inflammatory cytokine involved in the
progression and development of cancer. The family of TNF inhibits tumor formation
through apoptosis but TNFs deregulation encourages metastasis, migration and invasion of
tumor cell tissues [9]. TNFRSF10B gene consists of 10 gene coding exons. Sequence ana-
lysis of all exons suggested allelic loss of 8p was in 20 primary HNCs. A number of putative
tumors suppressor genes are located on 8p region which is a frequent site of translocations
in head and neck tumors. In 1998, 2-bp insertion in this gene at residue 1065 was found
that introduces a premature stop codon lead to truncated protein in SCCHN. Sequence
comparison between patient and normal tissues confirmed that germ line contains truncat-
ing mutation in the absence of p53 mutation [10].
In-silico analysis of TNFRSF10B gene was conducted to elucidate the novel mole-
cules, interacting partners, their binding interactions and to find a most plausible func-
tions. The main objective of our study was to design novel inhibitors. The aim of
research was to elucidate the interactions of TNFRSF10B protein with novel inhibitors
and to identify the relation of gene with disease.Results
The current work presents bioinformatics analysis of TNFRSF10B, a candidate gene of
HNC. TNFRSF10B gene mapped on chromosome 8, started from 22877646 bp and
Table 1 Molecular functions, biological processes and cellular locations of TNFRSF10B gene
Gene Molecular function Biological process Cellular location
Apoptotic process
Receptor activity Plasma membrane
Extrinsic apoptotic signalling pathway via
death domain receptors.
Protein binding Integral to membrane
TNFRSF10B Regulation of apoptotic process.
TRAIL binding
Activation of cysteine-type endopeptidase
activity involved in the apoptotic process.
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of TNFRSF10B gene are mentioned in Table 1.
Protein sequence of TNFRSF10B in FASTA format was retrieved from UniprotKB
with accession number E9PBT3. Table 2 represents the templates of TNFRSF10B pro-
tein selected on overall quality, total score and query coverage. All the three selected
templates were used for three dimensional structure predictions by comparative mod-
eling. The best model was built by MODELLER (9v10) [11] by using 2ZB9 template
with optimal alignment. Predicted model was visualized by Chimera 1.6 [12] shown in
Figure 1. Assessment of predicted structure by Rampage, ERRAT and ProSA is shown
from Figures 2, 3 and 4 respectively.
The evolutionary tool MEGA 5 [13] was employed to construct a neighbor-joining
tree of TNFRSF10B gene. Ensembl BLAST (http://www.ensembl.org/Multi/blastview) was
performed to identify paralogs of the target gene. Protein sequences of TNFRSF10A,
TNFRSF10D and TNFRSF10B were retrieved to determine the evolutionary relationship
between paralogs and orthologs. Numbers of bootstrap replications were 1000 in bootstrap
method. P-distance method and complete deletion option were used in the construction of
neighbor-joining tree shown in Figure 5.
Virtual screening technique
Virtual screening approach was employed to identify competitive compounds that in-
hibit the mutated TNFRSF10B activity. In pharmaceutical industry, the approach has
become progressively more popular for lead identification. The main objective of vir-
tual screening is to screen a large set of compounds against specific receptor protein to
identify the manageable number of inhibitors for possibly chance of lead to drug candi-
date [14]. Four lead compounds (A, B, C and D) structures were screened for further
analysis shown in Figure 6.
Bioavailability and membrane permeability are the molecular properties that al-
ways connected with molecular weight, partition coefficient (logP), number of hydrogenTable 2 Template aligned by high score and query coverage
Accession ID Total score Query coverage E-value Sequence identity
2ZB9 25.8 84% 5.4 30%
3NKE 25.8 46% 4.1 32%
3NKD 25.0 46% 8.1 32%
Figure 1 3D structure of TNFRSF10B protein visualized by the UCSF CHIMERA visualizing tool. A
model is presented in smoothing ribbons and sticks. Helixes are represented by blue colour and coils by
green colour.
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Lipinski “Rule of Five” was formulated by using these molecular properties [16].
According to this rule, molecules with good membrane permeability have log P≤5, mo-
lecular weight ≤500, hydrogen bond acceptors ≤10 and donors ≤5 [17]. Therefore,
Lipinski’s Rule of Five was applied to check the bioavailability characteristics such asFigure 2 RAMPAGE result of TNFRSF10B protein showing the distribution of residues in favored,
allowed and outlier regions.
Figure 3 ERRAT result of TNFRSF10B model showing the 51.85% overall quality of model. X-axis
shows the number of resides while the Y-axis represents error values of residues.
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In present work, these properties were determined by Mcule tool [18] mentioned
in Table 3.
Toxicity
High quality lead structures are the requirement for the successful drug discov-
ery and structures of drug properties are more acceptable than common [19]. In
the early steps of drug discovery, poor pharmacokinetics and toxicity should be
eradicated. Toxicity and drug score characteristics were further used to screen the
hits [20].
Docking analysis of TNFRSF10B protein with screened lead compounds was
performed by AutoDock and post dock analysis by Chimera 1.6v and Discovery
Studio. The amino acids present in the active sites of the protein were identified
by observing those amino acids in the vicinity of 4 Å. Residues of receptor pro-
tein interacting with compounds were calculated and presented in Figures 7 and 8
by Chimera and Discovery Studio respectively.
A functional partner network of TNFRSF10B protein was generated by the
STRING [21] and STITCH3 [22] databases to explore the highly interacting pro-
teins of the target protein. TNFSF10 protein having highest interaction score
0.999 with receptor protein was used as a ligand protein in protein-protein
docking by GRAMM-X [23] and Hex [24]. Interaction network and protein-
protein docked complex are shown in Figures 9 and 10 respectively. Interactions
of interacting residues were determined and analyzed by PyMol mentioned in
Table 4.
(A)Overall Model Quality Plot
(B)  Local Quality plot
Figure 4 ProSA results of TNFRSF10B model (A) Plot showing −1.08 Z-score representing the overall
quality of the model. (B) Local model quality plot of model showing position of sequences against
knowledge based energy in both window sizes 10 and 40.
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Figure 5 Neighbor-joining tree of TNFRSF10B gene showing TNFRSF10A gene as ancestral gene.
Topology of tree showing TNFRSF10A gene is out group of tree. Species having >50% bootstrap values are
presented in this tree.
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Head and neck cancer remains a disfiguring disease associated with a high mortality
rate [25]. Progressive accumulation of genetic aberrations leads to SCCHN but exact
nature is still unknown. Candidate gene identification approach may provide key factors
to pinpoint candidate genes involved in different carcinomas, which leads to explore
the receptor-ligand or protein-protein interactions recognize these carcinomas that
might lead to the development of effective therapeutic strategies [26].
For head and neck candidate gene TNFRSF10B, 2ZB9, 3NKE and 3NKD templates
were retrieved from PDB. Out of these three templates, 2ZB9 showed optimal align-
ment and query coverage. Rampage showed the 93.2% residues in favored region
and 5.7% in the allowing region whereas only 1 residue was in outlier region.
51.852% quality factor and −1.08 Z-score were shown by ERRAT and ProSA evalu-
ation tools respectively.
In literature, TNFRSF10B gene and its paralogs genes are predicted in primates and
human. MEGA 5 was employed using neighbor-joining method to determine evolu-
tionary relationship of genes among teleosts, rodents, birds, primates and mammals.
TNFRSF10D and TNFRSF10A are the paralogs of TNFRSF10B gene that are used in
the construction of a phylogenetic tree. TNFRSF10A gene is outgroup in TNFRSF10B
tree that presents TNFRSF10A gene as an origin of other genes. TNFRSF10A gene gave
rise to TNFRSF10B gene in Ciona Intestinalis and other cluster is further diverged into
TNFRSF10D and TNFRSF10B genes. Human and gorilla are closely related in
TNFRSF10B and TNFRSF10A genes while in TNFRSF10D, human is closely re-
lated with chimpanzee. Bootstrap replication values >50 are presented in phylo-
genetic tree representing the reliability of topology.
Novel designed molecules have drug related properties and served as inhibitors
for candidate gene. Interactions were observed in binding pocket of TNFRSF10B
showing polar nature of binding domain. The designed compounds fulfill the
properties of a competent drug and have no toxicity, mutagenic, irritants and car-
cinogenic property.
Figure 6 Chemical structures of screened lead compounds (A, B, C and D) used in docking analysis.
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protein belonging to the same protein family. TNFSF10 protein was used as a lig-
and for protein-protein docking with TNFRSF10B receptor protein. Post docking
analysis was performed by PyMol to analyze the hydrogen, ionic and hydrophobic
interactions. Only ionic interactions were found in docked complex. Isoleucine-58
of receptor protein TNFRSF10B showed ionic interactions with Arginine-130 of












A 130.077 −0.7977 0 2 4 0 ARG-23, GLU-24, ALA-25, ARG-26,
GLY-27, ALA-28, VAL-39, VAL-41,
LEU-46
B 158.303 −0.776 0 0 4 0 ARG-23, GLU-24, VAL-39, LEU-40,
VAL-41, ALA-43, LEU-46
C 789.86 3.5317 14 5 14 2 ILE-58, ALA-59, SER-60, ALA-62,
MET-73, ILE-85, GLN-86, TRP-89,
SER-90
D 807.877 3.65.05 14 5 15 2 PRO-9, ALA-10, SER-12, GLY-13,
LYS-16, ARG-17 PRO-30, GLN-53,
LYS-54, GLU-57
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showed interaction with oxygen atom of isoleucine. Serine-90 of TNFRSF10B recep-
tor protein showed ionic interactions with Serine-156 of ligand protein with a bond
distance of 3.2 Å. Nitrogen of serine of ligand protein TNFSF10 interacted with the
oxygen of serine of receptor protein. Alanine-62 nitrogen of receptor protein
TNFRSF10B interacted with arginine-130 oxygen of ligand protein TNFSF10 with
3.2 Å bond distance.Figure 7 Binding views of lead compounds (A, B, C and D) with TNFRSF10B receptor protein. The
compounds are depicted in pink sticks while protein structures in brown hetromeric surfaces. Interacting
residues of receptor protein docked with respective four (A, B, C and D) compounds are determined and
presented by Chimera.
Figure 8 Post dock analysis of complexes by Discovery Studio tool. Chemical structures of compounds
with interactions of receptor protein are shown. A) Interactions of novel designed compound A with receptor
protein. B) Compound B interacted with TNFRSF10B. C) Interacted complex of TNFRSF10B with designed C
inhibitor. D) Binding residues of compound D with receptor protein.
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For protein-protein interaction and novel designed molecules, both functional and ex-
pressional studies of TNFRSF10B showed significant interaction. In-vivo experimenta-
tion could be performed in animal model to check the effect of selected protein
interactions which may leads to the approved drug of head and neck cancer. More than
80% homology between human and primates are strong evidence to build ancestral re-
lationship which will help in prediction of protein functions and family. Current re-
search suggested a baseline for novel ligand screening, docking and ancestral hierarchy
for development and validation of novel drugs in particular function prediction of can-
didate gene TNFRSF10B.Materials and methods
The sequence of TNFRSF10B protein in FASTA format was retrieved from
Uniprot Knowledge base (http://www.uniprot.org/) of accession number E9PBT3.
The retrieved amino acid sequence of TNFRSF10B was subjected to a protein-
protein BLAST (BLASTp) search against the Protein Data Bank (PDB) (www.rcsb.org/)
[27] to recognize a suitable template structure. Suitable template [PDB ID: 2ZB9] having
84% query coverage, 30% sequence identity and 5.1 E-value was used in comparative
modeling of TNFRSF10B protein. The homology modeling program MODELLER 9v10
Figure 9 Interaction network of TNFRSF10B generated by STRING database. In this network TNFSF10B
protein showed the highest interaction score 0.999 with TNFSF10 protein. TNFSF10 protein is used in
protein-protein docking of TNFRSF10B.
Figure 10 Interaction analysis of TNFRSF10B and TNFSF10 visualized by PyMol tool.
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TNFRSF10B TNFSF10 Ionic bonding (N-O) ILE-58/O→ ARG-130/NH1 2.9
SER-90/O→ SER-156/N 3.2
ALA-62/N→ ARG-130/O 3.2
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tion was further assessed by Rampage [28], ERRAT [29] and ProSA [30] evaluation tools
for the reliability of predicted structure.
Molecular Evolutionary Genetic Algorithm (MEGA 5) was used to infer ancestral his-
tory and species relationship of TNFRSF10B gene. Distance based approach through
neighbor-joining technique was applied to construct the phylogenetic tree by using
1000 bootstrap replicates.
The compounds obtained through virtual screening were used in docking analysis by
AutoDock Vina [31]. The ligand molecules of target protein were not reported in earl-
ier studies and also not found in biological databases, hence virtual screening technique
was used to screen drug like lead compounds for TNFRSF10B docking calculations.
Four novel lead compounds (as A, B, C and D) were screened. Mcule suit was
employed for virtual screening and to predict the bioactivity and molecular properties
of lead compounds.
LogP value is an important predictor of per oral bioavailability of drug mole-
cules [32]. Therefore, physiochemical properties such as LogP, molecular mass, ro-
tatable bonds, hydrogen bond acceptor and donors of 4 selected lead compounds
were determined. Results showed that compounds (C and D) showed violations of
two rules of lipinski rule of five suggesting that lead compounds have good bio-
availability. The selected top scrutinized compounds were minimized through
VegaZZ [33] and ChemDraw Ultra [34]. Subsequent analysis on selected lead
compounds were carried out and docking analysis was performed to identify the
binding affinities by AutoDock. Parameters of AutoDock used in docking are
mentioned in Table 5.
The STRING and STITCH3 servers were employed to identify the functional part-
ners of TNFRSF10B. These databases are online database of known and predicted pro-
tein interactions including direct (physical) and indirect (functional) relationships.
Gramm-X and Hex online servers were applied in protein docking of TNFRSF10B pro-
tein with its interactive partner TNFSF10 protein. Post docking analysis of docked











A 5.52 61.778 35.2 40*40*40 0.02 0.8 −4.8
B 5.846 61.933 35.423 40*40*40 0.02 0.8 −4.9
C 5.846 61.933 35.423 40*40*40 0.02 0.8 −8.6
D 5.846 61.933 35.423 40*40*40 0.02 0.8 −9.9
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